FATE
FATE THERAPEUTICS INCCompany Information
- Company Name
- FATE THERAPEUTICS INC
- CIK
- CIK0001434316
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- FATE: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- FATE
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-12-20
- Last sale
- 2026-08-04
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 176,565
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 66,268,087
- Shares outstanding
- 120,397,390
- Ownership
- 55.04%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- -1.59%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 32 | 40 | 47 | 41 | 41 | 45 | 36 | 38 | 37 | 121 | 42 | 33 | ||||||
| Accounts Receivable Net Current | 1 | 1 | 1 | 1 | 1 | 2 | 4 | 4 | 1 | 1 | 2 | 2 | ||||||
| Short Term Investments | 121 | 135 | 157 | 175 | 182 | 196 | 243 | 259 | 268 | - | 273 | - | ||||||
| Prepaid Expense And Other Assets Current | 3 | 4 | 4 | 5 | 6 | 5 | 9 | 9 | 13 | 10 | 15 | 13 | ||||||
| Assets Current | 158 | 180 | 209 | 221 | 230 | 248 | 292 | 310 | 319 | 394 | 332 | 364 | ||||||
| Long Term Investments | 0 | 0 | 1 | 10 | 26 | 32 | 28 | 34 | 47 | 8 | 1 | 0 | ||||||
| Property Plant And Equipment Net | 52 | 54 | 57 | 59 | 61 | 63 | 64 | 82 | 88 | 92 | 97 | 102 | ||||||
| Operating Lease Right Of Use Asset | 41 | 41 | 42 | 42 | 44 | 45 | 47 | 58 | 60 | 61 | 62 | 63 | ||||||
| Restricted Cash Noncurrent | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 15 | 15 | 15 | 15 | ||||||
| Other Assets Noncurrent | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Contract With Customer Asset Net Noncurrent | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Assets | 260 | 285 | 319 | 344 | 372 | 399 | 441 | 495 | 529 | 570 | 506 | 544 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 3 | 3 | 3 | 4 | 4 | 4 | 9 | 6 | 5 | 7 | 5 | 6 | ||||||
| Accrued Liabilities Current | 15 | 14 | 20 | 18 | 18 | 17 | 21 | 24 | 23 | 32 | 28 | 29 | ||||||
| Contract With Customer Liability Current | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | ||||||
| Operating Lease Liability Current | 5 | 5 | 5 | 5 | 6 | 7 | 7 | 7 | 7 | 6 | 6 | 6 | ||||||
| Liabilities Current | 33 | 31 | 36 | 28 | 29 | 28 | 39 | 37 | 35 | 45 | 39 | 41 | ||||||
| Operating Lease Liability Noncurrent | 71 | 72 | 73 | 74 | 76 | 77 | 78 | 92 | 94 | 96 | 97 | 99 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 1,749 | 1,745 | 1,741 | 1,736 | 1,731 | 1,724 | 1,716 | 1,707 | 1,695 | 1,686 | 1,580 | 1,571 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | 0 | 0 | 0 | 0 | 0 | 1 | -0 | -0 | 0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -1,596 | -1,566 | -1,534 | -1,502 | -1,470 | -1,436 | -1,398 | -1,346 | -1,298 | -1,260 | -1,212 | -1,168 | ||||||
| Stockholders Equity | 153 | 180 | 207 | 234 | 261 | 288 | 319 | 362 | 397 | 426 | 368 | 403 | ||||||
| Liabilities And Stockholders Equity | 260 | 285 | 319 | 344 | 372 | 399 | 441 | 495 | 529 | 570 | 506 | 544 | ||||||
| Convertible Preferred Stock | 0 | 3 | 3 | 0 | 0 | 3 | 3 | 0 | 0 | 3 | 3 | 0 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Preferred Stock Shares Issued | - | - | - | - | - | - | - | - | 3 | - | - | - | ||||||
| Preferred Stock Shares Outstanding | - | - | - | - | - | - | - | - | 3 | - | - | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 350 | 350 | 350 | 350 | 350 | 250 | 2,500 | 250 | 250 | 250 | 250 | 250 | ||||||
| Common Stock Shares Issued | 117 | 116 | 115 | 115 | 115 | 115 | 114 | 114 | 114 | 114 | 99 | 99 | ||||||
| Shares Outstanding | 117 | 116 | 115 | 115 | 115 | 115 | 114 | 114 | 114 | 114 | 99 | 99 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialFATE THERAPEUTICS INC (FATE) — SEC Financial Statements & Analysis
FATE THERAPEUTICS INC (FATE) is a biological products, (no diagnostic substances) company. FATE THERAPEUTICS INC trades on Nasdaq as: FATE. FATE THERAPEUTICS INC (FATE)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, FATE THERAPEUTICS INC carries a market cap of $325.07M, a P/E ratio of -2.58x, a P/B ratio of 2.12x, a P/S ratio of 50.08x, an enterprise value of $292.64M, and an EV/EBITDA multiple of -2.41x. On profitability, it posts an operating margin of -2058.08%, a net margin of -1941.09%, a Return on Equity (ROE) of -60.75%, a Return on Assets (ROA) of -39.89%, and a Return on Invested Capital (ROIC) of -78.25%. Per share, it reports EPS of $-1.05, diluted EPS of $-1.05, free cash flow per share of $-0.88, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -23.36% year-over-year, net income growth of -26.54% year-over-year, and EPS growth of -27.68% year-over-year. On the balance sheet, it maintains a current ratio of 4.85x, a quick ratio of 4.74x, working capital of $125.36M, a debt-to-equity ratio of 0.21x, a debt ratio of 0.13, free cash flow of $-105.62M (TTM), and net debt of $-32.43M. Figures sourced from SEC EDGAR.
- Market Cap
- $325.07M
- P/E TTM
- -2.58x
- EPS TTM
- $-1.05
- P/B TTM
- 2.12x
- ROE TTM
- -60.75%
- ROA TTM
- -39.89%
- Debt To Equity
- 0.21x
- Free Cash Flow TTM
- $-105.62M
- Net Revenue TTM Growth 1Y
- -23.36%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is FATE THERAPEUTICS INC in?
FATE THERAPEUTICS INC (FATE) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does FATE trade on?
FATE THERAPEUTICS INC (FATE) trades on the Nasdaq.
When was FATE THERAPEUTICS INC (FATE)'s most recent SEC filing?
FATE THERAPEUTICS INC (FATE)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is FATE's market cap?
FATE THERAPEUTICS INC (FATE) has a market capitalization of $325.07M as of 2026-06-30.
What is FATE's EPS (earnings per share)?
FATE THERAPEUTICS INC (FATE)'s trailing twelve month EPS is $-1.05 as of 2026-06-30.
What is FATE's ROE (return on equity)?
FATE THERAPEUTICS INC (FATE)'s trailing twelve month Return on Equity (ROE) is -60.75% as of 2026-06-30.
What is FATE's ROA (return on assets)?
FATE THERAPEUTICS INC (FATE)'s trailing twelve month Return on Assets (ROA) is -39.89% as of 2026-06-30.
What is FATE's ROIC (return on invested capital)?
FATE THERAPEUTICS INC (FATE)'s trailing twelve month Return on Invested Capital (ROIC) is -78.25% as of 2026-06-30.
What is FATE's EV/EBITDA?
FATE THERAPEUTICS INC (FATE)'s trailing twelve month EV/EBITDA is -2.41x as of 2026-06-30.